To reach the next value inflection
LicenseRx asset brief
Next-Generation 5-HT-2B Serotonin-Receptor Antagonists for Anti-Fibrotic & Cardiopulmonary Therapy
Probability of Success
24% · grade C · Medium data confidence
Model PoS 24% (grade C, medium data confidence). Strongest signals: Data maturity, Indication pull. Biggest drag: IP position.
Data maturity (22%)
59
Preclinical; in vivo data.
IP position (16%)
30
Protection lapsed or abandoned -- verify freedom to operate.
Modality feasibility (14%)
70
Delivery tech -- feasible when attached to a validated payload.
Indication pull (14%)
78
Inflammation, Oncology -- active buyer appetite.
Competitive whitespace (12%)
66
Crowded oncology field; multi-modal differentiation.
Translational evidence (12%)
70
Public evidence mentions: in vivo, mouse, potency.
Licensing readiness (10%)
94
Listed as available for licensing; established tech-transfer office; 1 public source link(s).
Unlock the full strategic deep dive
Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.
View Operator access See what's included →